Skip to main content
OpenTrials
Completed

NCT Number: NCT03839979

HCV Viral Hepatitis, Blood Sugar Level and Systolic Blood Pressure in Egypt

An observational double-blind cohort study that examined the association between HCV viral hepatitis, blood sugar level and systolic blood pressure in the Egyptian population

Completed

Looking for future studies?

Notify Me

Key information

About this study

a cohort study on greater than 70000 Egyptian patients had been conducted. for all patients,1- we detected the Hepatitis C Virus (HCV) RNA antigens ( hepatitis C virus)presence using BIOLINE HCV kits( qualitative test for diagnosis of hepatitis C virus in the blood), For all positive patients, confirmatory rapid screening test was performed and all patients who tested positive twice underwent a qPCR test using QIAampMinElute Virus Spin kit (Thermo Fisher Scientific, Waltham, MA, USA) performed according to the manufacturer's recommended protocol.

2- Investigators measured blood sugar levels for each patient using ACCU-CHEK kits(finger stick sugar level measurement) 3- Measured systolic blood pressure for each patient was measured using mercury meters.

4-for all patients investigators obtained full medical history regarding the presence or absence of chronic diabetes, chronic hypertension, coronary artery disease, kidney impairment with dialysis or chronic obstructive pulmonary disease.

5- for all patients investigators listed age, gender, and body mass index. 66121 patients were negative for HCV and 4852 were positive for HCV. Investigators measured the association between HCV presence, high blood sugar levels and high systolic blood pressure.

It is supposed that this is the largest study in the world that examined both associations.

In a word, this study was responding to a specific question: is hepatitis c virus presence is associated with high blood pressure or high sugar level or both or not associated???

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Egyptian citizens from 18 years to 80 years.

Exclusion criteria

  • Patients younger than 18 years or older than 80 years

Treatment and study plan

BIOLINE HCV kits

Diagnostic Test

We used BIOLINE HCV kits to detect the presence of HCV antibodies in stick blood samples of all recruited patients.

Other names: diagnosis of viral hepatitis C

ACCU-CHEK kits

Diagnostic Test

For all patients, we measured random blood sugar levels by stick blood samples using ACCU-CHEK kits.

Other names: measurement of blood sugar level

ErKameter 3000 mercury manometer

Diagnostic Test

For all patients, we measured systolic blood pressure using ErKameter 3000 mercury manometer.

Other names: blood pressure measurement

Primary outcomes

  1. HCV diagnosis

    Time frame: 20 minutes

    Detection of patients who are HCV positive or negative

  2. Measurement of blood sugar level in mg/dl

    Time frame: 1 minute

    Detection of the percentage of patients with high blood sugar level in HCV positive or negative patients

  3. Measurement of systolic blood pressure in mmHg

    Time frame: 1 minute

    Detection of the percentage of patients with high systolic blood pressure in HCV positive or negative patients

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Registry information

Official study title

Association Between HCV Viral Hepatitis, Blood Sugar Level and Systolic Blood Pressure in the Egyptian Population

Important dates

Study start
2018
Primary completion
2018
Study completion
2019
First posted
Feb 15, 2019
Registry last updated
Mar 18, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.